BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) for the intranasal delivery of a mRNA COVID vaccine. This innovative direction aims to offer an alternative to traditional injection-based vaccines, leveraging a technology designed to improve safety and adaptability.
MET, a non-lipid polymer delivery system, represents a potential breakthrough in vaccine administration by reducing side effects often associated with lipid-based delivery mechanisms. Instead of injections, this approach mirrors delivery methods like FluMist, offering a needle-free option for patients with needle aversions.
Virpax’s expertise with MET underpins this exploration, as the company has already applied the technology to its drug candidates Envelta (NES100) and NobrXiol (VRP324). Envelta, an intranasal enkephalin product for pain management, utilizes nanotechnology to penetrate the blood-brain barrier, while NobrXiol is designed to deliver cannabidiol for epilepsy treatment using MET to transport nanoparticles directly to the brain via the olfactory nerve.
The company believes that adopting MET for mRNA vaccine delivery could address longstanding challenges associated with injectable formulations, enhancing patient compliance and safety. Virpax has previously received regulatory guidance from the U.S. Food and Drug Administration for its NobrXiol program, further reinforcing its commitment to utilizing advanced drug delivery systems to improve care.
By exploring MET for vaccine delivery, Virpax underscores its innovative approach to pharmaceutical development, aiming to offer safer and more accessible therapeutic solutions for a range of conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.